Aslan Bullish On Once-Monthly Dosing For Eblasakimab In Atopic Dermatitis

 
• By Jessica Merrill

A Phase IIb trial testing the IL-13 inhibitor in atopic dermatitis demonstrated solid efficacy when dosed once every four weeks, but the market is competitive and dominated by Sanofi/Regeneron’s Dupixent.

raise the bar
Aslan says it raised the efficacy bar in AD; investors aren't as sure • Source: Shutterstock

More from Clinical Trials

More from R&D